The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial

NCT04562428 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Xiang Sha Liu Jun Zi Decoction dry powder
DRUG: XSLJZ Placebo

Sponsor

China Medical University Hospital